Julio Pascual, MD; José L. Teruel, MD; Joaquín Ortuño, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: In reviewing the use of erythropoietin in patientsreceiving dialysis, Dr. Nissenson (1) asserts that the drug itself has no known direct pressor activity. Preliminary clinical and experimental data indicate that this probably is not the case (2-4). In a patient receiving hemodialysis with hypertensive encephalopathy after 8 weeks of therapy with erythropoietin, Edmunds and Walls (2) observed that the rate by which hemoglobin concentration rose was modest and that the final value was similar to that achieved with transfusions on previous occasions. Baskin and Lasker (3) recently reported the cases of five patients who had important increases
Pascual J, Teruel JL, Ortuño J. Hypertensive Effect of Erythropoietin. Ann Intern Med. 1991;114:1063. doi: 10.7326/0003-4819-114-12-1063_1
Download citation file:
Published: Ann Intern Med. 1991;114(12):1063.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use